Facing the first fine in its 29-year history, the drug maker Genzyme turned to Covington & Burling and Hogan Lovells for counsel in striking a proposed settlement with the federal government over allegedly contaminated drugs, court records show.
Under the terms of the proposed consent decree, Cambridge, Mass.–based Genzyme, which specializes in expensive drugs aimed at treating rare genetic disorders, will pay a $175 million penalty and submit to a strict regime of government oversight that could last up to eight years, according to the Boston Globe and The Associated Press.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]